Climb Bio CLYM Institutional Ownership

Climb Bio, Inc. (NASDAQ:CLYM) showed up in the 13F filings of 111 institutional investors as of June 2026.

• Collectively, these holders controlled 74.1% of Climb Bio's outstanding shares in June 2026, up from 47.3% in March 2026.
• Their total shares held in CLYM increased 116.86% from the prior quarter, while the number of investors in Climb Bio increased 65.67% year over year.
• During the quarter, 86 of these 111 funds increased positions in CLYM, 18 reduced exposure, and 7 held steady.
• Combined, these investors held 56.43Mn shares in CLYM for June 2026, up by 30.41Mn shares quarter on quarter, and up 6.7Mn shares year over year.
• RA CAPITAL MANAGEMENT, L.P. is the top holder of Climb Bio as of June 30, 2026, with 11.3Mn shares representing 14.84% of outstanding stock.
• The biggest buyers of Climb Bio for the quarter ending June 2026 included FMR LLC (6.78Mn), UBS Group AG (3.32Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.51Mn), Cormorant Asset Management, LP (2.11Mn), BlackRock, Inc. (1.95Mn).
• The largest sales of CLYM for the quarter ending June 2026 came from MILLENNIUM MANAGEMENT LLC (368.06K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (357.12K), GREAT POINT PARTNERS LLC (334.13K), TWO SIGMA INVESTMENTS, LP (162.37K), Verdad Advisers, LP (98.42K).
• According to Business Quant data, leading holders of CLYM for June 2026 are RA CAPITAL MANAGEMENT, L.P. (11.3Mn), FMR LLC (6.79Mn), UBS Group AG (3.4Mn), BRAIDWELL LP (2.8Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.51Mn), BlackRock, Inc. (2.35Mn), PRICE T ROWE ASSOCIATES INC /MD/ (2.13Mn), Cormorant Asset Management, LP (2.11Mn), FRONTIER CAPITAL MANAGEMENT CO LLC (1.94Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.7Mn).